Next-Generation AI-Powered Platform for Aquablation® Therapy to Treat Benign Prostatic Hyperplasia (BPH) – Enlarged Prostate
WEST PALM BEACH, Fl.-December 13, 2024 – Good Samaritan Medical Center is the first hospital in South Florida outside of Miami to perform Aquablation® therapy with the new HYDROS™ Robotic System, the next-generation platform to treat men suffering from benign prostatic hyperplasia (BPH), commonly known as an enlarged prostate. The procedure was completed by robotic and minimally invasive urologic surgeon Dr. Joshua S. Jue.
“Being the first hospital in our community to offer this procedure keeps us at the forefront of medical technology investment. It gives our patients the best opportunity at a positive outcome,” said Sheri Montgomery, the hospital’s CEO. “We always put the patient first so they can get back to enjoying a quality lifestyle.”
Aquablation therapy, now delivered by an AI-powered robotic system, is clinically proven to provide significant, durable BPH symptom relief while preserving sexual function and continence across prostates of all shapes and sizes.
BPH is an unfortunate reality of aging for millions of men, which is commonly associated with lower urinary tract symptoms. Common urinary symptoms associated with BPH include frequent daytime urination, waking at night to urinate, straining to urinate, slow urinary stream, sensation of incomplete bladder emptying, and urgency to quickly use the restroom. Without timely treatment, BPH can lead to severe health issues such as permanent bladder or kidney damage, infections, bladder stones, and urinary incontinence. Half of males ages 51-60 have BPH1 and 99% of men say BPH impacts their quality of life2.
Aquablation therapy was designed to offer a minimally invasive and effective solution for BPH that can be applied to almost all prostate gland sizes. Aquablation therapy is unique in its use of real-time, ultrasound-guided, robotic-assisted waterjet technology, allowing surgeons to create a personalized treatment plan that precisely targets prostate tissue to remove or preserve. With this tailored approach, the system accurately removes obstructing tissue, while protecting apical prostate tissue.
The HYDROS Robotic System represents the next evolution in the delivery of Aquablation therapy. Leveraging insights from over 50,000 procedures, HYDROS features FirstAssist AI™ treatment planning, advanced image guidance, robotic resection, and a streamlined workflow. HYDROS is designed to improve efficiency, enhance surgeon and staff experience, and deliver a more accurate and consistent treatment plan for better clinical outcomes.
Dr. Jue has been performing this operation in Manhattan using the first-generation platform, AquaBeam™ Robotic System, since 2021. At the time of his first operation at Good Samaritan Medical Center, the new HYDROS™ Robotic System was not available in New York City.
“I am proud to offer this new surgical treatment that leverages AI technology to South Florida. Artificial intelligence integration is becoming the future of innovation, and I am happy to see that this technology is becoming integrated into robotic surgery to improve patient outcomes. Quality healthcare that utilizes the latest technology is available in South Florida at Good Samaritan Medical Center,” said Dr. Jue.
For more information on urological services at Good Samaritan Medical Center, please visit www.palmbeachhealthnetwork.com.
About Good Samaritan Medical Center
Good Samaritan Medical Center (GSMC) is a 333-bed acute care hospital, part of the Palm Beach Health Network, that’s provided sophisticated, personalized and emergency medical care to Palm Beach County and the Treasure Coast with over 100 years of experience.
GSMC utilizes some of the latest robotic technologies that highlight their robust general surgery procedures including the MAKO, Da Vinci and Velys robots. Our cancer center is accredited by the Commission on Cancer, anchored by our state-of-the-art Breast Center.
To learn more about GSMC visit www.palmbeachhealthnetwork.com or call 561-650-6023.
Risk and Safety Information
All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam® Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.
As with any surgical urologic procedure, potential perioperative risks of the Aquablation procedure include but are not limited to the following, some of which may lead to serious outcomes and may require intervention: Anesthesia risk, Bladder or prostate capsule perforation, Bladder neck contracture, Bleeding or blood in the urine, Bruising, Penile or pelvic pain, Irritative symptoms, which may include dysuria, urgency or frequency, Infection, Transurethral resection (TUR) syndrome, Electric shock/burn, Urethral damage causing false passage or stricture, Rectal incontinence/perforation, Sexual dysfunction, including ejaculatory and erectile dysfunction, Incontinence or overactive bladder, Embolism, Urinary Retention.
Rx Only
Please review the Instructions for Use and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions, and potential adverse events.
© 2024 PROCEPT BioRobotics Corporation. All rights reserved. AQUABLATION, HYDROS, PROCEPT BioRobotics, and the PROCEPT BioRobotics logo are trademarks and/or registered trademarks of PROCEPT BioRobotics Corporation. ML0636.A
